Earnings Miss: Tongwei Co.,Ltd Missed EPS And Analysts Are Revising Their Forecasts
It's been a good week for Tongwei Co.,Ltd (SHSE:600438) shareholders, because the company has just released its latest first-quarter results, and the shares gained 2.1% to CN¥21.70. It was a pre
What Qingdao Vland Biotech INC.'s (SHSE:603739) 26% Share Price Gain Is Not Telling You
Qingdao Vland Biotech INC. (SHSE:603739) shares have continued their recent momentum with a 26% gain in the last month alone. Unfortunately, despite the strong performance over the last month, the
A three-pronged approach! Tongwei Co., Ltd. strengthens investor confidence with its strength: full strength in increasing holdings, repurchases, and dividends
“Investor Network” Wang Jianfan In 2023, the global photovoltaic market achieved 444 GW of new installed capacity, an increase of 76% over the previous year. Among them, China took the lead, contributing 216.88GW, with a growth rate of 148%, leading the world for 11 consecutive years. Although demand continues to grow, the release of large production capacity on the supply side has led to an imbalance between supply and demand, causing prices in the industrial chain to fall and industry competition to intensify. As can be seen from the disclosure of the quarterly reports of major photovoltaic companies, the industry is currently facing significant operating pressure and market adjustments. In the face of challenges, Tongwei Co., Ltd. has shown a solid ability to withstand risks. Tongwei Co., Ltd. 2023/4
Jefferies Adjusts Tongwei's Price Target to 29.32 Yuan From 33.52 Yuan, Keeps at Buy
05:13 AM EDT, 04/30/2024 (MT Newswires) -- Jefferies Adjusts Tongwei's Price Target to 29.32 Yuan From 33.52 Yuan, Keeps at Buy Price (RMB): ¥21.70, Change: ¥-0.79, Percent Change: -3.51%
*ST Toyo (002086.SZ) reported first-quarter results with a net loss of 14.3898 million yuan
*ST Toyo (002086.SZ) released its report for the first quarter of 2024. The company achieved revenue during the reporting period...
Tiankang Biotech (002100.SZ): Net profit of 54.638 million yuan for the first quarter reversed the year-on-year loss
Gelonghui, April 29丨Tiankang Biotech (002100.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 3.777 billion yuan, down 2.93% year on year; net profit attributable to shareholders of listed companies was 54.638 million yuan, which turned a year-on-year loss into a profit; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 56.773 million yuan; basic earnings per share were 0.04 yuan.